Moberg Pharma (MOB) Q2 2026 earnings summary

Executive summary

• Achieved significant progress in international commercialization of MOB-015, expanding collaboration with Karo Healthcare to new markets including APAC and China.

• TerclaraⓇ (MOB-015) maintained market leadership in Sweden and Norway, with strong pharmacy sales shares in both value and units.

• Regulatory approvals in 13 European countries, with launches planned in additional markets and first deliveries outside Nordics expected around year-end.

• Strengthened management team and board to support upcoming product launches and international expansion.

Financial highlights

• Net revenue for Jan–Jun 2026 was SEK 10.7 million, up from SEK 7.5 million year-over-year.

• EBITDA for the six-month period improved to SEK -5.8 million from SEK -13.1 million year-over-year.

• Operating profit (EBIT) for Jan–Jun 2026 was SEK -6.6 million, compared to SEK -13.9 million year-over-year.

• Profit for the period was SEK -4.5 million, an improvement from SEK -10.2 million year-over-year.

• Cash and cash equivalents at period end were SEK 212.4 million, down from SEK 254.7 million a year earlier.

Outlook and guidance

• Focus remains on commercializing MOB-015 in approved European markets, with launches in additional countries planned as regulatory approvals for Karo Healthcare branding are obtained.

• Collaboration with Karo Healthcare provides broad market coverage and rapid commercial reach.

• Priority given to markets with existing partnerships and high commercial potential.